ACYW135群脑膜炎球菌结合疫苗在3月龄婴儿中的Ⅲ期临床试验
该研究采用随机、盲法、同类疫苗对照设计,在720名3月龄健康婴儿中比较ACYW135群脑膜炎球菌结合疫苗与A群C群脑膜炎球菌多糖结合疫苗的安全性和免疫原性。结果显示试验疫苗总体不良反应发生率低于对照疫苗,且对C群抗体GMT及≥1∶128比例优于对照,对A群免疫原性与对照相当。
要点
- 试验疫苗总体不良反应发生率21.90%,低于对照疫苗32.04%(P<0.001)。
- 试验疫苗C群抗体GMT 43.53高于对照27.28(P<0.001)。
- 试验疫苗A群抗体阳转率91.42%与对照92.92%无统计学差异(P>0.05)。
核心结论
- ACYW135群脑膜炎球菌结合疫苗应用于3月龄婴儿后具有更好的安全性和免疫原性。
研究设计与样本
- 2017年2月至2018年6月在河南省疫苗临床研究基地开展的随机、盲法、同类疫苗对照临床试验。
- 受试者为3月龄健康婴儿共720名,按1∶1比例随机分配到试验组和对照组。
- 按3、4、5月龄接种程序分别接种试验疫苗(ACYW135群脑膜炎球菌结合疫苗)和对照疫苗(A群C群脑膜炎球菌多糖结合疫苗)。
- 第1针次接种720名,第2针次接种696名(试验组346名,对照组350名),第3针次接种692名(试验组344名,对照组348名)。
主要发现
- 试验疫苗总体不良反应发生率为21.90%(230例),低于对照疫苗的32.04%(339例)(P<0.001)。
- 试验疫苗全身不良反应发生率为19.52%(205例),低于对照疫苗的27.69%(293例)(P<0.001)。
- 试验疫苗局部不良反应发生率为3.04%(32例),低于对照疫苗的7.84%(83例)(P<0.001)。
- 试验疫苗3级不良反应发生率为0.57%(6例),低于对照疫苗的2.36%(25例)(P<0.001)。
- 试验疫苗A群抗体阳转率91.42%、C群88.76%与对照疫苗92.92%、87.02%相比差异无统计学意义(P>0.05);Y群和W135群抗体阳转率分别为88.17%(298例)和99.41%(336例)。
关键数值与推荐
- 试验疫苗A群抗体GMT为56.24,对照疫苗为57.43(P>0.05)。
- 试验疫苗C群抗体GMT为43.53,高于对照疫苗的27.28(P<0.001)。
- 试验疫苗Y群和W135群抗体GMT分别为89.22和140.66。
- 试验疫苗C群抗体GMT≥1∶128的比例为31.07%(105例),高于对照疫苗的16.22%(55例)(P<0.001)。
临床怎么用
- 该疫苗在3月龄婴儿中按3、4、5月龄程序接种,总体不良反应发生率低于对照疫苗。
- 对C群免疫原性优于对照疫苗,对A群免疫原性与对照疫苗相当。
- 可考虑将ACYW135群脑膜炎球菌结合疫苗纳入3月龄婴儿的免疫规划。
局限性
- 研究仅在河南省疫苗临床研究基地开展,结果外推需考虑地区差异。
- 随访观察不良反应时间为接种后0~30天。
- 未报告长期保护效果和更多人群亚组数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: The aim of this study was to evaluate the safety and immunogenicity of the first domestic ACYW135 meningococcal conjugate vaccine and a control vaccine named AC group meningococcal conjugate vaccine for 3 months (90-119 days) infants. Methods: From February 2017 to June 2018, a randomized, blinded, and similar vaccine-controlled clinical trial design was adopted at the Henan Vaccine Clinical Research Base. The subjects were 3 months old healthy infants, a total of 720, based on a 1∶1 ratio. The random allocation table for entry was randomly assigned to the experimental group and the control group. According to the 3, 4, and 5 month-old vaccination procedures, the subjects were vaccinated with test vaccine (ACYW135 group meningococcal conjugate vaccine) and control vaccine (group A group C meningococcal polysaccharide conjugate vaccine), of which 720 were given the first dose, 696 were given the second dose (test group: 346; control group: 350), and 692 were given the third dose (test group: 344; Control group: 348). Results: The overall adverse reaction rate of the test vaccine was 21.90% (230 cases), which was lower than the 32.04% (339 cases) of the control vaccine (P<0.001). The incidence of systemic adverse reactions was 19.52% (205 cases), which was lower than that of the control vaccine (27.69%) (293 cases) (P<0.001). The local adverse reaction rate was 3.04% (32 cases), which was lower than the control group (7.84%) (83 cases) (P<0.001). The graded adverse reaction test vaccine was 0.57% (6 cases), which was lower than the control group of 2.36% (25 cases) (P<0.001). The positive conversion rate of anti-bacterial serum antibodies showed that there was no significant difference between the test vaccine group A (91.42%), C (88.76%) and the control vaccine (92.92%) (87.02%) (P>0.05). Group Y and W135 was 88.17% (298 cases), 99.41% (336 cases), respectively. The GMT results showed that the test vaccine group A was 56.24, the control vaccine was 57.43 (P>0.05); the group C test vaccine (43.53) was higher than the control group (27.28) (P<0.001). The group Y and W135 are 89.22 and 140.66, respectively. Among them, the proportion of the group C GMT antibody ≥ 1∶128 for test vaccine (31.07%, 105 cases) was higher than the control vaccine (16.22%, 55 cases) (P<0.001). Conclusion: ACYW135 group meningococcal conjugate vaccine has more safety and immunogenicity after application to 3 month old infants. 目的: 评价国产ACYW135群脑膜炎球菌结合疫苗应用于3月龄婴儿后的安全性和免疫原性。 方法: 2017年2月至2018年6月在河南省疫苗临床研究基地采用随机、盲法、同类疫苗对照的临床试验设计,受试者为3月龄健康婴儿,共720名,按1∶1比例依据入组随机分配表随机分配到试验组和对照组,按照3、4、5月龄接种程序对研究对象分别接种试验疫苗(ACYW135群脑膜炎球菌结合疫苗)和对照疫苗(A群C群脑膜炎球菌多糖结合疫苗),其中第1针次接种720名,第2针次接种696名(试验组:346名;对照组:350名),第3针次接种692名(试验组:344 名;对照组:348 名)。采用定期随访与主动报告相结合的方式,观察疫苗接种后0~30 d内所有与疫苗有关的不良反应,在接种疫苗前和完成基础免疫后30 d分别采集约3.0 ml静脉血,用于检测和比较试验组和对照组的免疫原性。 结果: 试验组对象总体不良反应发生率为21.90%(230例),低于对照组对象的32.04%(339例)(P<0.001),其中试验组对象全身不良反应发生率为19.52%(205例), 低于对照组对象的27.69%(293例)(P<0.001);试验组局部不良反应发生率为3.04%(32例), 低于对照组对象的7.84%(83例)(P<0.001);试验组3级不良反应发生率为0.57%(6例), 低于对照组对象的2.36%(25例)(P<0.001)。抗体阳转率结果显示,试验疫苗A群(91.42%)、C群(88.76%)与对照疫苗(92.92%)、(87.02%)相比差异无统计学意义(P>0.05),试验疫苗Y、W135群抗体阳转率分别为88.17%(298例)和99.41%(336例)。试验组对象A群抗体GMT为56.24,对照组为57.43(P>0.05);试验组对象C群抗体GMT(43.53)高于对照组(27.28)(P<0.001);试验组对象Y、W135群抗体GMT分别为89.22和140.66。试验组C群抗体GMT≥1∶128的比例(31.07%,105例)高于对照疫苗(16.22%,55例)(P<0.001)。 结论: 国产ACYW135群脑膜炎球菌结合疫苗应用于3月龄婴儿后具有更好的安全性和免疫原性。.
引用
- Xie ZQ, Zhao DY, Huang HT, et al. [A phase Ⅲ clinical trial study on the safety and immunogenicity of ACYW135 group meningococcal conjugate vaccine inoculated in 3 month old infants]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020. PMID: 32907283. doi:10.3760/cma.j.cn112150-20200520-00758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。